A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia

Journal of Clinical Psychopharmacology

Volumn 18, Issue 5, 1998, Pages 399-403

  Lee, Min Soo ^a   Kim, Yong Ku ^a   Lee, Sang Kyu ^a   Suh, Kwang Yoon ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; HALOPERIDOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; AFFECT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SERTRALINE;

EID: 0008762402     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199810000-00008     Document Type: Article

References (23)

1. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153:466-76.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenics: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
3. Goff DC, Brotman AW, Waites M, McCormick S. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990;147:492-4.
4. Syvalahti EKG, Kallioniemi H, Lehto H. Citalopram in patients with unsatisfactory response to neuroleptics: an open follow-up study. Methods Find Exp Clin Pharmacol 1994;16:49-55.
5. Thakore JH, Berti C, Dinan TG. An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Psychiatr Scand 1996;94:194-7.
6. th Annual Meeting of the American Psychiatric Association, 22-27 May 1993, San Francisco, California; Washington DC: American Psychiatric Association, 1993:76.
7. Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Di-Risa AE, Caputi AP. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994;9:281-5.
8. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 1995; 117:417-23.
9. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double, placebo-controlled study. Biol Psychiatry 1992;31:698-704.
10. Salokangas RKR, Saarijarvi S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, Tuominen J, Ahola V, Syvalahti E. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996;94:175-80.
11. Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RJ. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 1991;148:790-2.
12. Sommi RW, Crismon ML, Bowden CL. Fluoxetine: a serotonin-specific, second-generation antidepressant. Pharmacotherapy 1987;7:1-15.
13. Jenner P, Sheehy M, Marsden CD. Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. Br J Clin Pharmacol 1983;15[suppl 2]:277S-289S.
14. Hamilton M. Rating scale of depression. J Neurol Neurosurg Psychiatry 1960;23:56-62-19.
15. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212[suppl]:11-19.
16. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. In: Kaplan HI, Sadock BJ, eds. Comprehensive textbook of psychiatry. Baltimore: Williams & Wilkins, 1989:1591-626.
17. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Biol Psychiatry 1987; 20:219-22.
18. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, 1976:218-22.
19. Viala A, Arymard N, Leyris A, Carola F. Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate. Therapie 1996;51:19-25.
20. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996: 11[suppl 5]:31-61.
21. Crow TJ. The two-syndrome concept: origins and current status Schizophr Bull 1985;11:471-85.
22. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995;152: 827-32.
23. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.